Shots:

• The US FDA has approved the NDA for Ryaltris, a fixed-dose, aqueous suspension, prescription drug product nasal spray for the treatment of symptoms of seasonal allergic rhinitis in adults and pediatric patients aged ≥12yrs.
• Ryaltris will be available in the US by Hikma, following an exclusive license agreement with Glenmark & a recommended daily dose is 2 sprays, BID in each nostril. The product has been marketed in Australia, the Czech Republic, Poland, Russia, South Africa, Ukraine, Uzbekistan & the US
• The company has signed commercial agreements with multiple partners globally including Menarini to commercialize Ryaltris in the EU and with Bausch Health in Canada 

 Ref: PR Newswire | Image: The Hindu Business Line